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Abstract: cDNA fragments covering the whole envelope (E) protein region of hepatitis C
virus (HCV) have been molecularly cloned by using polymerase chain reaction (PCR) techni-
que from the serum of five HCV infected patients in Nagasaki Prefecture. Their nucleotide
and encoded amino acid sequences were determined and compared with other HCV cDNA
clones isolated in Japan and the United States. The result showed that HCV cDNA isolates
compared in this study were roughly divided into two subgroups; Japanese subgroup and
USA subgroup. All HCV cDNA isolates in Nagasaki Prefecture were included in the former
subgroup. Amino acid homology analysis showed that conformation of the E protein was
relatively conserved among all compared HCV cDNA isolates, indicating that the E protein
may be under structural or functional constraint.
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Polymerase chain reaction
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INTRODUCTION
Blood-borne non-A, non-B hepatitis (NANBH), which is caused by viral infection, is a
major form of post-transfusion hepatitis (Feinstone, 1975) and frequently develops into
chronic hepatitis and malignant liver diseases such as cirrhosis and hepatocellular carcinoma
(Dienstag, 1983; Kiyosawa et at., 1984, Koretz et al., 1980; Realdi et at., 1982; Resnick et at.,
1983). Recently, CDNA clones of probable hepatitis C virus (HCV) have been obtained by im-
munoscreening of CDNA library derived from the plasma of a chimpanzee chronically in-
fected with HCV in the United States (Choo et al, 1989). Using these clones, they subse-
quently developed an immunoassay to detect specific anti-HCV antibodies (anti-ClOO) (Kuo et
at., 1989). Seroepidemiological studies based on the detection of anti-ClOO indicated that
HCV not only is the major cause of post transfusion NANBH but also may have a pathogenic
role in many cases of chronic liver disease (Alter et al, 1989; Kuo et al, 1989; Miyamura et
al, 1990; Plageman, 1991; Saito et al, 1990). More recently, several research groups in
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J apan have isolated cDNAs spanning partial or total length of HCV genome directly from
human patients by using probes based on the sequence of the prototype isolates in the
United States (Kato et al., 1990; Okamoto et al., 1990; Takamizawa et al., 1991; Takeuchi et
aL, 1990). From their analyses on primary structure of the viral genome, the HCV genome is
considered to be a positive-stranded RNA molecule of about 10,000 nucleotides which en-
codes a large polyprotein precursor of about 3,000 amino acids. A search for sequence
homology of the HCV genome indicated that this virus is related to flaviviruses and
pestiviruses (Houghton et al, 1988; Miller and Purcell, 1990). The gene products of HCV
have not been identified, but HCV genome organization was speculated as shown in Figure 1
(Takamizawa et aL, 1991), by comparing deduced amino acid sequence of the long open
reading frame (ORF), its hydrophobicity profile, and the location of potential glycosylation
sites with those of pesti- and flavivirus genomes. The HCV viral genome encodes one large
polyprotein that is subsequently cleaved into three structural proteins, the core (C) protein,
the matrix (M) protein, the envelope (E) protein, and six nonstructural proteins, NS1, NS2,
NS3, NS4a, NS4b, and NS5. It is known that the epitopes which are recognized by the
neutralizing antibodies exist on the E protein region in the case of flaviviruses. Therefore,
the E protein region would become the first target for vacccine development of HCV infec-
tion. In this study, by using polymerase chain reaction (PCR), a technique for DNA amplifica-
tion in vitro (Saiki et aL, 1988), a CDNA fragment of HCV genome which encodes the total E
protein region have been molecularly cloned from the serum samples of 5 patinets with acute
and chronic HCV infection in Nagasaki Prefecture. Their nucleotide and deduced amino acid
sequences were comparatively analyzed with those of the HCV cDNAs isolated so far in
other parts of Japan and in the United States in order to analyze the molecular epidemiology
of local strains. These informations may also be useful for the strategies to develop the HCV
vaccine.
MATERIALS AND METHODS
Preparation of RNA from human serum samples; Serum samples obtained from
NANBH infected patients in Nagasaki Prefecture which were kindly provided by the Second
Department of Internal Medicine of Nagasaki University Hospital were used. The serum
samples were first screened the presence of anti-ClOO by using Ortho Diagnostic enzyme-link-
ed immunosorbent assay kit according to the manufacturer's instruction. In the cases of
chronic NANBH infection, anti-ClOO positive serum samples were selected and used for
RNA extraction. In the cases of acute NANBH infection, the serum samples were used for
RNA extraction regardless of the presence of anti-ClOO because it is known that the detec-
tion of anti-ClOO during acute phase of HCV infection (especially within one month since
HCV infecton) is usually difficult (Alter et aL, 1989; Kuo et aL, 1989). To extract RNA, 100
fA serum was made up to 200 fA with sterile distilled water and mixed with an equal volume
of buffer containing 0.2 M "tris" -HC1 (pH 7.5), 25 mM ethylenediaminetetra-acetic acid (ED-
TA), 0.3 M NaCl, 2% sodium dodecyl sulfate (SDS), and 200 fig/ml proteinase K, and in-
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cubated at 37°C for 40 min. Proteins were removed by two extractions with phenol and once
with chloroform. Twenty micrograms glycogen was added to the aqueous phase and the
RNA was precipitated by addition of three volumes of ice-cold absolute ethanol. After
storage at -70°C for 1 hr, the RNA was pelleted in an Eppendolf centrifuge (30 min,
15,000 x^, 4°C). The pellet was washed once in 70% ethanol, vacuum dried, and dissolved in
50 fA sterile distilled water. RNA solution was stored at -70°C.
Primers for PCR reaction: The oligonucleotide primers were synthesized with an Ap-
plied Biosystems DNA synthesizer (model 380B) and confirmed for purity by ion-exchange
gel chromatography (Gen-pack; Waters). The sequences of primers were 5'-GTAATTTGG-
GTAAGGTCATCGATAC-3 '(sense) and 5 '-TGCCAACTCCCATTGGTGTT-3Xantisense). This
primer pair was expected to amplify 868 base pair DNA from putative region covering the
whole E protein (nucleotide position: 707-1574) according to the sequences reported by
Takamizawa et al. (1991) (Fig. 1).
Reverse-transcription (RT)-PCR: Five microliters of RNA solution was added to 95 p\
of RT-PCR mixture containing 100 pmol each primers, 0.2 mM each deoxynucleoside
triphosphate, 10 mM Tris (pH 8.9), 1.5 mM MgCl2> 80 mM KC1, 0.5 mg of bovine serum
albumin per ml, 0.1% sodium cholate, 0.1% Triton X-100, 10 U of reverse transcriptase (Life
Science Inc.), and 2 U of Tth DNA polymerase, a thermostable DNA polymerase (Toyobo
Co.). The reaction mixture was covered by 2 drops of mineral oil, and the tube was in-
cubated for 10 min at 53°C for RT. PCR amplification (92°C for 60 sec, 53°C for 90 sec, and
72°C for 120 sec by thermal cycler; Iwaki Co.) was started immediately after the RT and
repeated 35 times. PCR product was subjected to 3% agarose gel electrophoresis, and
amplified DNA fragments were visualized by ethidium bromide staining.
Cloning and sequencing of HCV CDNA: The CDNA fragment amplified by RT-PCR
was excised from the agarose gel, phosphorylated with T4 polynucleotide kinase (Nippon
Gene Co.) and blunted with T4 DNA polymerase (Takara Co.). The modified DNA fragment
was subcloned into the Smal site of pUC19. The nucleotide sequence of the isolated clone
was determined by the dideoxy chain termination method (Sanger et al., 1977).
CDNA
Fig. 1. Tentative genome organization of HCV according to Takamizawa et al. (1991) and
mapping of CDNA clone. Nucleotides are numbered from the extreme 5' end as in-
dicated at the top. A proposed genetic organization of the HCV genome is indicated,
with coding regions for the C, M and E protein as well as nonstructural proteins (NS1
to NS5) shown as block, the 5' as well as 3' non-coding regions as bars. A thin box
below HCV genome represent CDNA clones from PCR products which has been
amplified from the serum of the HCV infected patients in Nagasaki Prefecture.
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Comparison of nucleotide and amino acid sequences: The amino acid sequence was
deduced from the nucleotide sequence of the cloned HCV CDNA, and the sequence of the E
protein region was tentatively assigned by analysis of the putative cleavage sites and the
hydrophobicity profiles of the encoded proteins according to the method reported by
Takamizawa et al (1991). The nucleotide and amino acid sequences of the E protein region
of HCV cDNAs isolated in Nagasaki Prefecture and others were compared. These com-
parisons were carried out with computer analysis by using DNASIS-Mac Version 1.0 soft-
ware system (Hitachi Co., 1991).
RESULTS
Isolation of the CDNA clones of HCV: by RT-PCR, target DNA fragments could be
amplified from five patients' serum samples and were isolated as five distinct CDNA clones
of HCV in Nagasaki Prefecture, designated as HCV-JN1-HCV-JN5. Brief clinical profile of
each patient is showed in Table 1. Two of them were acute hepatitis with history of blood-
borne infection (HCV-JN1 and HCV-JN5). Remaining three were chronic hepatic diseases
without apparent history of blood transfusion, therefore their routs of infection were
unknown.
Nucleotide sequences of the E gene of isolated HCV cDNAs: Figure 2 showed the
nucleotide sequence of the E gene of HCV-JN1, an isolate in Nagasaki Prefecture, as well as
the nucleotides that differ from this sequence for the four isolates in Nagasaki Prefecture
(HCV-JN2-JN5), the five isolates in other parts of Japan; HCV-JYK (Takeuchi et al,
Table 1. Clinical profiles of the patients from whose sera HCVs in Nagasaki Prefecture have
been cloned by PCR
P t N o .
A g e/S e x
D a te o f se r u m C lin ic a l
H isto ry o f
b lo o d
tr a n s fu s io n
A L T le v e l a t A n ti C - 1 0 0
(v ir u s iso la te ) s a m p lin g d ia g n o s is s a m p lin g re a c tiv ity
1 (H C V - J N l) 4 9 /m a le '8 6 . 7 . 9 P T - A H *3 + 1 , 9 2 5
2 (H C V - J N 2 ) 5 8/m a le '8 7 . l l . 19 C H ( - 1 1 4 H + )
3 (H C V - TN 3 ) 5 3/m a le '8 7 , 10 .2 2 H C C + L H ( - 9 7 H + )
4 (H C V - J N 4 ) S B/m a le '8 7 . 7 . 15 C H 1 1 7 ( + H
5 (H C V - J N 5 2 6 /m a le '8 6 . 12 . 6 A H *b ( - 1 , 7 9 4 ( - )
The abbreviations used in clinical diagnosis represents AH; acute hepatitis, PTAH; post-transfu-
sion acute hepatitis, CH; chronic hepatitis, HCC; hepatocellular carcinoma, LC; liver cirrhosis respec-
tively.
*a: HCV has been transmitted from the blood transfused during gingival cancer operation.
*b: This patient is a clinical doctor and HCV has been transmitted from a post-transfusion acute
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Fig. 2. Nucleotide sequences of the E genes of eleven HCV isolates, HCV-JN1-JN5 HCV-
JYK, HCV-JGC, HCV-JBK, HCV-JJ1, JJ2, and HCV-US (nucleotides were numbered
from the extreme 5' end of the E gene). Only the changes from HCV-JN1 sequences


















































































































































































































































































































































































































































1990), HCV-JGC (Kato et al, 1990), HCV-JBK (Takamizawa et al., 1991), HCV-JJl and HCV-
JJ4 (Okamoto et al., 1990), and the prototype isolate in the United States; HCV-US (Choo et
al., 1991). This figure showed that the nucleotide differences were scattered throughout the
length of the gene, and there appeared to be no particular region of hypervariability. The
numbers of nucleotide differences and the identity percent of the necleotidies between each
of these isolates were summarized in Table 2 (a) and (b), respectively. These results in-
dicated that the isolate in the United States (HCV-US) was less closely related to the isolates
in Japan except for HCV-JJl. Except HCV-JJl, HCV-US showed an average of 25.5%
nucleotide sequence difference with all Japanese HCV CDNA islates, and the difference
among Japanese isolates was in the range from 4.2% to 12.1% (average 9.1%). HCV-JJl,
which was isolated from a HCV healthy carrier in Japan, was closely related to HCV-US
showing 94.6% nucleotide sequence identity. Although pairs of other isolates in Japan show-
ed similar nucleotide sequence identity each other, there was a pair of isolates which showed
less nucleotide difference; HCV-JN2 and HCV-JN5, both of which were isolated in Nagasaki
Prefecture, showed a 96.3% identity.
Amino acid differences in the E protein of HCV isolates: The encoded amino acid se-
quences of the E protein from HCV-JN1 isolate was shown, in the standard one letter code,
in Figure 3, with different amino acids noted for the other isolates. Five potential N-
glycosylation sites were found from the amino acid sequence of the E protein of HCV-JN1.
Twoof them were completely conserved in all other isolates. In the remaining three sites,
amino acid sequences were different in some other isolates. But in two of these sites, the pat-
tern of the amino acid sequence (N-X-T/S) were conserved in all other isolates. Various
amino acid differences among HCV strains were scattered throughout the E protein, and
there appeared to be no particular region of hypervariability. Table 2 (a) and (b) summarized
the amino acid differences and identities percent between these isolates. These results in-
dicated that HCV-US and HCV-JJl were less closely related to other Japanese isolates,
similar to the nucleotide sequences comparison. The amino acid identity percent between
each isolate were similar to those of the nucleotide identity indicating that most of the muta-
tions were not silent. The difference between the amino acid sequence homology percent
calculated by using the Dayhoff scoring matrix (Dayhoff and Schwartz, 1978) and the amino
acid sequences identity percent were shown in Table 3. Homology among each isolates in-
cluding also HCV-US and HCV-JJl showed high matching figure (average 95.9%), compared
with those of the identity (average 87.1%) indicating that many of the mutations were not
silent, but were neutral (conservative). Figure 4 showed the amino acid sequence of the E
protein of HCV-JN1 isolate, as well as the amino acids that were not homologous with this se-
quence for the other HCV isolates. There appeared to be three conserved regions (AA
no.l-25, no.81-106, no.122-192). Figure 5 showed the relation of the hydrophobicity pro-
file of the E protein of HCV-JN1 clone using Hopp and Woods's program (1981) that is
useful for prediction of protein antigenic determinants, and the locations of these three con-
served regions. Several hydrophilic portions were observed on region A, but few on region B
andC.
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Table 2. (a) Nucleotide and predicted amino acid differences among eleven HCV isolates




H C V - H C V - H C V - H C V - H C V - H C V - H C V - H C V - H C V - H C V - H C V -
TN I  JN 2  JN 3  JN 4  JN 5  TY K JG C  JB K  JJI  JJ4  U S
H C V -






H C V -
JN 2 7 1        19   21   12   15   19   20   47   16   46
H C V -
JN 3
60   65        17   16   14   17   20   47   14   44
z H C V -
JN 4 65   72   57        17   18   13   13   4 8   13   43
H C V -
JN 5 6 1   25   58   56        14   14   19   47   12   41
H C V -
JY K 55   48   44   52   39        13   18   44   12   43
H C V -
JG C 52   7 1   57   57   56   49        14        ll   41
H C V -
JB K 67   62   52   56   54   54        47   16   43
H C V -
JJl 157   167   166   160   158   158   160   156        44
H C V -
JJ4
49   58   51   48        37   50   49   156        43
H C V -
u s 160   158   153   151   151   150   14 4   147   33   14 7
N um b ers abov e th e d iagon al rep resent am in o acid differen ces am on g th e H C V isolates, w hile those
elow th e diag on al rep resen t n u cleotide d ifferences.
(b) Nucleotide and predicted amino acid identity % among eleven HCV isolates
in the gene coding for the envelope protein
AMINO ACID
H C V - H C V - H C V - H C V - H C V - H C V - H C V - H C V - H C V - H C V - H C V -
TN I J N 2 J N 3 J N 4 J N 5 J Y K J G C J B K J J l J J 4 u s
H C V -
J N l
9 3 . 9 % 9 6 . ( 9 7 . ( 9 6 .5 % 97 .( 6 .5 % 9 5 .( 93 .4 % 9 6 .5 % 9 2 . % 4
H C V -
J N 2
8 7 .9 % 9 6 . 5 % 9 6 . ( 6 . 5 % 9 6 . 5 % 9 4 .4 % 9 7 .0 % 9 1 . 4% 9 6 .( 9 3 .(
H C V -
J N 3
9 0 . ( 9 . 4 % 9 8 . 0 % 9 7 . 5 % 9 8 . 5 % 9 6 .5 % 9 7 . 5 % 9 2 .< 9 8 .0 % 9 4 . 4 %
H C V -
J N 4
8 9 . 1 % 8 .4 % 9 0 . i 9 8 . 5 % 99 . ( 9 7 .0 % 9 7 . 0 % 9 3 . 0% 9 8 . 0 % 9 4 . 4 %
H C V -
J N 5
9 . 6 % 9 6 . 3 % 9 0 . 2 % 9 0 . 4 % 98 . 5 % 9 6 .5 % 9 6 . 5 % 9 2 .4 % 9 7 . 5 % 9 3 . 9 %
H C V -
J Y K
9 0 . 6 % 9 2 .4 % 9 2 . 6 % 9 1 . 4 % 9 3 .6 % 9 8 -{ 9 7 . 5 % 9 3 . 4% 9 8 .5 % 9 5 . (
H C V -
J G C
9 1. 1% 8 . 6 % 9 0 . ; 9 0 . 2 8 9 . 9 % 9 1 . 6 % 9 6 .5 % 9 4 . ( 9 6 . 5 % 9 5 .(
H C V -
J B K
8 8 . 4 % 8 8 . 9 % 9 . 4 % 9 0 . 4 % 9 0 . 2 % 9 0 .9 % 9 0 . 6 % 9 3 . 4 % 9 7 .0 % 9 5 . (
H C V -
J J l
7 3 .6 % 7 2 .( 7 2 . 2 % 7 3 . 1 % 7 3 . ^ 7 3 . 4 % 7 3 . 1 % 7 3 . ( 9 3 .4 % 9 8 . 5 %
H C V -
J J 4
9 1. 6 % 9 0 .7 % 9 1. 4 % 9 1 . 8 % 9 2 . < 9 3 . 6 % 9 1 . 3 % 9 1 . 4 % 7 3 . 6 % 9 4 . 4 %
H C V -
u s







Numbers above the diagonal represent amino acid identity % among the HCV isolates, while those
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Fig. 3. Envelope protein sequences derived by the translation of the nucleotide sequences
shown in Fig. 1 of eleven HCV isolates (amino acid were numbered from the extreme
5' end of the E protein). Only the amino acids that differ from HCV-JN1 are indicated
for the other isolates. The identical amino acids are given as bars. The five potential
N-glycosylation sites (N-X-T/S) are underlined.
T able 3. Amino acid homology % and identity % among eleven HCV isolates
of the envelope protein
AMINO ACID HOMOLOGY
H C V - H C V - H C V - H C V - H C V - H C V - H C V - H C V - H C V - H C V - H C V -
J N l J N 2 J N 3 JN 4 JN 5 J Y K J G C J B K J J l 1 14 u s
H C V -
J N l
9 3 .9 % 9 6 .0 % 9 7 .( 9 6 . 5 % 9 7 . 0 % 9 6 . 5 % 9 5 . 0 % 9 3 . 4 % 9 6 . 5 % 9 2 . % 4
H C V -
J N 2
8 7 .; 6 .5 % 9 6 . 0 % 6 . 5 % 9 6 . 5 % 9 4 . < 9 7 . 0 % 9 1 . 4 % 9 6 . 0 % 9 3 . 0 %
H C V -
J N 3
8 9 .9 % 9 0 . 4 % 9 8 .0 % 9 7 . 5 % 9 8 .5 % 9 6 . 5 % 9 7 . 5 % 9 2 . 9 % 9 8 . 0 % 9 4 . 4 %
H C V -
J N 4
9 .9 % 8 9 .4 % 9 1 .4 % 9 8 .5 % 9 9 . 0 % 9 7 . 0 % 9 7 . 0 % 9 3 . 0 % 9 8 . 0 % 9 4 . 4 %
H C V -
J N 5
8 .9 % 9 3 .9 % 9 2 .0 % 9 1 .4 % 9 8 . 5 % 9 6 . 5 % 9 6 . 5 % 9 2 . ; 9 7 . 5 % 9 3 . 9 %
H C V -
J Y K
9 1 .4 % 9 2 .4 % 9 2 .9 % 9 1. 0 % 9 2 . 9 % 9 8 . ( 9 7 . 5 % 9 3 . 4 % 9 8 . 5 % 9 5 . 0 %
H C V -
J G C
9 2 .< 9 0 . ^ 9 1. 4 % 9 3 .' 9 2 . ｣ 9 3 . 4 % 9 6 . 5 % 9 4 . 0 % 9 6 . 5 % 9 5 . 0 %
H C V -
J B K
8 .9 % 9 .9 % 8 9 .9 % 9 3 .4 % 9 0 .' 9 1 . ( 9 2 . 9 % 9 3 . 4 % 9 7 . 0 % 9 5 . 0 %
H C V -
J J l 7 5 .3 %
7 6 .3 % 7 6 .3 % 7 5 .8 % 7 6 . 3 % 7 7 . 8 % 7 6 . 8 % 7 6 . 3 % 9 3 .4 % 9 8 - 5 %
H C V -
J J4
9 2 .0 % 9 2 .0 % 9 2 .9 % 9 3 . 4 % 9 3 . 9 % 9 3 . 9 % 9 4 .4 % 9 2 . 0 % 7 7 . 8 % 9 4 . 4 %
H C V -
u s












Numbers above the diagonal represent amino acid homology % among the HCV isolates, while
those below the diagonal represent nucleotide identity % same as numbers above the diagonal in
Table2(b).
Evolutional relationships among the HCV isolates: According to the method to
calculate evolutional difference (Ks) between two homologous nucleotide sequences
reported by Miyata and Yasunaga (1980), Ks for each pair of the compared HCV CDNA
isolated has been calculated by using "EVO-DNA4" computer program (Okumura and
Izui, 1990) (the program soft has been provided by Dr. K. Izui, Department of Chemistry,
Faculty of Science, Kyoto University). Based on the Ks values, phyrogenetic relatinships
among compared HCV CDNA isolates were determined by the unweighted pair-group
method (Sneath and Sokal, 1973) (Fig. 6). From this result, HCV CDNAisolates compared
in this study were roughly divided into two groups; the first group contains HCV-US and
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Fig. 4. Envelope protein sequences of eleven HCV isolates as same as shown in Fig. 3. The
amino acids that are not homologous to HCV-JN1 are indicated. The homologous
amino acids are given as bars. The sequence regions in where amino acids homology














Fig. 5. Hydrophilicity profile of E protein from HCV-JN1. The bold bars given as region A,
B, C indicate the location of the highly conserved sequence regions shown as boxed
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The comparison of nucleotide and amino acid sequences among various HCV CDNA
isolates and the phyrogenetic tree calculated from these results showed that there was no
closer relationships among the isolates in Nagasaki Prefecture compared with those in other
parts in Japan. The result indicated that the compared HCV CDNAisolates in Japan, except
HCV-JJ1, were included in one large subtype (Japanese subtype), and a isolate in the United
States (HCV-US) was distinct from this subtype. HCV-JJ1 was considered to belong to the
HCV-US because of its sequence relatedness. The nucleotide and amino acid differences
were scattered throughout the length of the E protein region, and no particular hypervariable
or conserved region was observed. Although the amino acid identity between each pair of the
compared isolates showed some variation (75.3%^97.5%, average 87.1%), the amino acid
homology based on the Dayhoff scoring matrix was well conserved (91.4%~99.0%, average
95.9%) among all isolates including US subtype strains. While seve ^1 highly conserved
region were observed in the E protein sequence, indicating that many of amino acid muta-
tions in the E protein region were conservetive. This result suggests that conformation of the
HCV E protein is relatively conserved, indicating that the E protein region may be under
structural or functional constraint. From the comparison with hydrophobicity profile of the E
protein, one of the conserved region (region A in Fig. 5) may possibly contain the antigenic
domain which function as neutralizing epitopes. Recently, Matsuura et al. (1991) expressed
the HCV E protein gene as a 35 kDa glycoprotein (gp35) by using a recombinant
baculovirus. By Western blot analysis using expressed gp35 as antigen, they tried to detect
antibodies to gp35 in the sera from NANBH patients. From this experiment, they got follow-
ing observations. Antibodies to gp35 were detectable in only 4%-11% of NANBH patients,
not only in acute hepatitis but also chronic hepatic diseases (chronic hepatitis, liver cirrhosis,
and hepatocellular carcinoma). In two of the acute hepatitis and one of the chronic hepatitis
cases, patients have been recovered from hepatitis after appearance of anti-gp35 antibodies.
The serum alanin aminotransferase level has been generally kept at lower level in the anti-
gp35 seropositive chronic disease patients. These results raise two possibilities: ( i ) gp35
does not contain neutralizing epitopes or has very low immonogenicity, but has some func-
tions to inhibit viral proliferation, ( ii ) although gp35 contains neutralizing epitopes, their an-
tigenic structure is different among various HCV because of the hypervariability of amino
acid sequences. From the results presented in this parer, the second possibility does not
seem to be probable. On the other side, some researchers proposed that the hypervariable
region which exists in the NS1 region carries potential neutralizing epitopes and suggested
the mechanism resembling to the second possibility mentioned above that make lead to the
persistent infection of HCV (Hijikata et al, 1991; Kremsdolf et al, 1991; Weiner et al., 1991).
At present, several speculations and suggestions are under discussion concerning this
problem. To get more precise and useful information, further experiments on HCV and
establishment of the cell culture system for HCV will be necessary.
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